Elicio Therapeutics

Small biotech developing lymph-node-targeted KRAS vaccines for pancreatic and colorectal cancer.

ELI-002 7P (amphiphile mKRAS vaccine); AMPLIFY-7P phase 2 missed its primary endpoint in June 2026; phase 3 strategy being refined.

Headquarters

Boston, MA, US

Type

biotech · ELTX

Website

elicio.com

Products

1top

Phase 2Off-the-shelf lymph-node-targeted KRAS peptide vaccine

ELI-002 7P

A ready-made vaccine against the seven commonest KRAS mutations, given after pancreatic cancer surgery. Its phase 2 missed the main goal in 2026 but showed signs of activity.

Connected

3top

Elicio Therapeutics

Products

Connected

cancers

drugs

bottlenecks